Iridius, a startup based in Seattle, has successfully secured $8.6 million in seed funding aimed at automating compliance processes for AI systems in regulated industries, particularly pharmaceuticals. The investment round was led by Chalfen Ventures with contributions from Accenture Ventures, Osage Venture Partners, and Rock Yard Ventures. This funding will facilitate the development of technology that translates regulatory requirements into code, ensuring compliance is enforced in real-time during AI operations.
Founded in 2024 by former Microsoft executives Mike Kropp and Alistair Lowe-Norris, Iridius aims to address significant compliance challenges faced by pharmaceutical companies, which can spend up to $1.5 billion annually on regulatory adherence. The startup’s solutions are designed to log agent actions automatically for auditing purposes.
Initially overlooked, the need for AI compliance technology gained traction as major pharmaceutical firms encountered compliance issues late in their AI pilot programs. Through collaboration with Accenture and Microsoft, Iridius plans to identify opportunities for compliance automation that can enhance efficiencies in drug development.